TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

NCT04891900 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

25

Enrollment

OTHER_GOV

Sponsor class

Conditions

Gastric Cancer
Adenocarcinoma of Esophagogastric Junction

Interventions

DRUG: TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine

Sponsor

Henan Cancer Hospital